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Summary.-Sera from breast cancer patients and from female controls were tested
for inhibition of lysis of antibody-coated target cells by human leucocytes (K cells).
Sera from39 ,' of breast cancer patients, but from only8° of controls, inhibited lysis
by more than 30%O. This inhibition was unrelated to the stage of the disease, the
patient's age or whether the patient was pre- or post-operative. Inhibition was
apparently not due to anti-HLA antibodies and did not correlate with the IgG level
or anti-complementary activity of the serum. On fractionation by gel-filtration,
inhibitory activity was found in fractions of higher molecular weight than IgG.
As no IgG could be detected in these fractions, inhibition is probably not due to
immune complexes containing IgG antibody. The inhibitory factor may well
contribute to the immunosuppressed status of a proportion of breast cancer patients.
MANY cancer patients have impaired
immunological competence, especially
later in the course of their disease. The
basis of this impairment remains largely
unknown, although sera from patients
with widely different cancers can depress
T lymphocyte function in vitro as
measured by PHA stimulation (Silk,
1967; Whittaker, Rees and Clark, 1971;
Gatti, 1971). Sera from breast cancer
patients can also reduce E rosette for-
mation, another T lymphocyte property
(Whitehead et al., 1976). However, the
effect of cancer serum on the function of
other types of lymphoid cell appears to
have been relatively unexplored. In this
study, sera from breast cancer patients
have been tested for inhibition of K cell
function. K cells are non-phagocytic
lymphoid cells responsible for killing
antibody-coated target cells (Perlmann
and Holm, 1968; MacLennan and Loewi,
1968). This mechanism is potentially of
importance in tumour rejection (Hersey,
1973).
MATERIALS AND METHODS
Patients.-Patients ranged in age between
37 and 83 years (mean ± s.d., 59-8 + 12-2)
and were attending an outpatients breast
cancer clinic. None of these women had
received chemo- or radiotherapy in the
previous 12 months. All patients were
staged using clinicopathological data accord-
ing to the TNM classification; Stage 1,
T1_2NoMo; Stage 2, T1_2N1M0; Stage 3,
T3 4No-2Mo; Stage 4, T1 4N0 3M1 where
T, N and M represent respectively tumour
size, the number of lymph nodes involved,
and whether or not there is metastasis. The
mean ages of the patients in the 4 stages
were: Stage 1, 60-2 i 13-9; Stage 2, 60-1 +
12-6: Stage 3, 59-7 11-5; Stage 4, 57-9 ±
12-0.
Controls-.Controls were healthy women,
mostly laboratory or office staff aged between
41 and 72 years (mean 53-3 + 7-9).
Sera.-Blood was obtained by vene-
puncture, allowed to clot at room tempera-
ture for 30 min and kept at 4°C for 2 h
before collection of the serum by centrifuga-
tion. Sera were either stored at 4°C and
used within 1 week of collection, or stored
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at -20°C until required. To avoid aggrega-
tion of IgG, sera were not heat-activated,
but left overnight at room temperature
before assay to remove the bulk of the
complement activity.
Inhibition of K cell killing.-Sera were
tested for their capacity to inhibit lysis of
antibody-coated Chang target cells by K cells
(MacLennan and Loewi, 1968). Normal
human leucocytes from laboratory personnel
were used as the source ofK cells.
Peripheral blood leucocytes were obtained
from heparinized blood by Hypaque/Ficoll
centrifugation and washed x 3. Although
the leucocyte suspension contained up to
15% monocytes and polymorphs, these cells
did not lyse antibody-coated Chang cells-
as shown by separate experiments using
plastic adherence to remove the phagocytic
cells.
Chang liver cells (106) were labelled with
51Cr (Brunner et al., 1968), incubated for
30 min at 37°C with 1 ml of a 1/500 dilution
of rabbit anti-human fibroblast serum, and
washed twice. This is a sub-complement-
fixing amount of antiserum. The anti-
serum was raised by giving 3 weekly in-
jections of 106 cells and bleeding 1 week after
the last injection.
Sera (25 ,ul) were dispensed into the
wells of Microtest II plates (Falcon Plastics)
and 75 ,ul of a human leucocyte suspension
(1.5 x 105 cells) was added, followed by
100 ,ul of a suspension of 51Cr-labelled,
antibody-coated Chang cells (104). After
17 h incubation at 37°C in 5% C02:95% air,
100 ,lI of supernatant was removed for
y counting. Each test was set up in
quadruplicate, using Eagle's minimum
essential medium containing 10% foetal
calf serum as diluent. Inhibition of cyto-
toxicity was calculated from the formula
100 (a-b)/(a-c) where a, b and c are the
mean ct/min 51Cr released from antibody-
coated Chang cells by respectively, leucocytes
+ medium, leucocvtes + test serum, and
medium alone. The %51Cr released by
medium alone or by leucocytes + medium
ranged from 17% to 35% and from 80% to
95% respectively (10 experiments). The
standard deviation of quadruplicate cultures
was always less than 7% of the mean, and
usually less than 5%. For all ofthe lympho-
cyte donors used, " spontaneous " killing of
non-antibody-coated Chang cells was less than
10%, and hence this effect was not taken
into account when calculating inhibition of
lysis of antibody-coated Chang cells. In each
test, sera from controls and from cancer
patients were included, and the data from all
tests were plotted in Fig. 1.
Rheumatoid factor estimation.-The Rose-
Waaler method was employed. Sera were
tested for agglutination of rabbit IgG-
coated sheep erythrocytes.
Erythrocytes (1%, v/v) were incubated
for 30 min at room temperature with an
equal volume of rabbit anti-sheep erythro-
cyte serum (Wellcome Reagents), diluted 10
times beyond its haemagglutination titre.
Equal volumes of the coated cells and test
serum dilutions were incubated overnight at
4°C in round-bottomed microplates (Cooke
Engineering). Results were expressed as
the minimum serum dilution which
agglutinated at least halfofthe cells. Before
testing, all sera were absorbed with sheep
erythrocytes.
HLA typing.-Sera were tested by the
NIH lymphocytotoxicity technique (Brand
et al., 1970) against selected lymphocytes,
covering the following HLA antigens: HLA-
A 1, 2, 3, 9, 11, 28, 29, w30, w31, w32.
HLA-B 5, 7, 8, 12, 14, 18, 27, w15, w16,
w17, w21, w22, w35, w40. Typing was
kindly performed by Mr C. Darke at the
Welsh Regional Transfusion Centre, St
Fagans.
Estimation of IgG levels.-The radial
immunodiffusion method was used (Mancini,
Carbonara and Heremans, 1965).
Serum fractionation by gel-filtration.-
Sera (1 ml) were fractionated at room
temperature on a (1-5 x 90) cm column of
Ultrogel AcA34, equilibrated with sterile
Dulbecco's phosphate-buffered saline, pH 7.5.
A flow rate of 3 ml/h was used and 2-ml
fractions were collected at 4°C. Appropriate
fractions were pooled and sterilized using a
0-2-,um filter.
Inhibition of complement (C') fixation.
Sera were tested for inhibition of C'-depen-
dent lysis of antibody-coated sheep erythro-
cytes.
Thrice-washed erythrocytes (1 ml packed
cells) were incubated for 45 min at 37°C
with 50 ml of a 1/500 dilution of rabbit
haemolysin (Wellcome Reagents) in C' fixa-
tion buffer (Oxoid), washed once and re-
suspended at 2% (v/v) in C' buffer containing
1% foetal calf serum. Fresh guinea-pig
serum was used as C' and titrated against an
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equal volume of sensitized erythrocytes in
flat-bottomed Microtest II plates (Falcon
Plastics). A C' dilution of 8 minimum
haemolytic units was used for inhibition
tests. Equal volumes (50 pul) of test serum
dilutions and C' were incubated at 3700
for 30 min. Inhibition was expressed as the
lowest serum dilution which caused inhibition
of haemolysis. Sera which inhibited at
dilutions > 1 in 8 were considered anti-
complementary.
Statistical tests.-The Fisher exact proba-
bility test was used.
RESULTS
Inhibition oflysis by K cells
Fig. 1 compares the capacity of sera
from normal individuals and from cancer
patients to inhibit lysis of antibody-
coated Chang cells by K cells. Most of
the normal sera inhibited by less than
30%, with only 2 out of 26 sera (8%)
above this limit. Breast cancer sera
exhibited a wider range of inhibition,
with clusters of values below and above
30%. Of the total of 84 breast cancer
sera tested, 33 (i.e. 39%) inhibited by
more than 30%. When the patient sera
were grouped into stages, the proportions
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which inhibited by more than 30% were:
Stage 1, 9 of 23 (39%); Stage 2, 6 of 17
(35%); Stage 3, 13 of 28 (46%); Stage 4,
5 of 16 (31%). By the Fisher exact
probability test, there is significantly
higher inhibition than normal sera
(P < 0.05) by Stage 1, 2 and 3 sera and
by pooled breast cancer sera: for Stage 4,
P 0 053. Inhibition did not correlate
with the age of the patient (correlation
coefficient = 0.12).
The reproducibility of the assay is
shown in Table 1. Individual sera tested
on different occasions against different
K cell donors had comparable activity.
In addition, sera taken from the same
individual at different times and tested
on different occasions gave similar results.
This inhibition of K cell killing may
be due to a number of mechanisms.
Firstly, IgM rheumatoid factor in the test
serum could inhibit, by masking the Fc
part of the anti-Chang cell IgG antibody
(IgM does not bind to K cells). To
investigatethis, inhibitory sera (i.e. >30%
inhibition) were tested for rheumatoid
factor (RF) by the Rose-Waaler test.
Of 21 inhibitory cancer sera tested, only 2
had detectable RF activity.
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FiG. 1. Comparison of normal and breast cancer sera for inhibition of K cell lysis of antibody-coated
Chang cells. Each point represents serum from a different individual.
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TABLE I.-Inter-experiment Variation
in Serum Inhibition of K Cell Lysis
Serum Leucocyte % Inhibition
donor* donor oflysis
1
2
3at
3b
4a
4b
5a
5b
6a
6b
A
B
C
C
D
C
D
D
C
D
B
E
D
E
0 7
9-1
6X0
68-5
80-4
6 8
-4-8
-7-4
5-4
12*5
36 5
54.7
51 0
67-0
* Sera were tested in separate experi.
ments against K cells from a range of
donors.
t a and b refer to sera taken from the
same patient on different dates.
Secondly, the presence of anti-HLA
antibodies in sera could cause inhibition
at the K cell level. Anti-HLA antibodies
can be detected in multiparous women
and in patients after blood transfusion.
It was considered that the first variable
could be allowed for by using age-matched
female controls. However, as many of
the breast cancer patients were tested
post-operatively (i.e. post-transfusion), it
was important to compare the inhibitory
activity of sera from pre-operative and
post-operative patients. From Fig. 2 it
can be seen that sera of pre-operative
patients were at least as inhibitory as post-
operative sera. There are 2furtherlinesof
evidence against a role for anti-HLA anti-
bodies: (a) none of 6 "inhibitory" sera
tested against a pool of typed lymphocyte
donors had detectable anti-HLA activity;
(b) in one experiment, 20 breast cancer sera
were tested against Kcells from 2 donors
of different HLA type, and found to have
a similar order of inhibitory activity-
consistent with the data in Table I.
K cell function can be inhibited by
aggregated IgG or by immune complexes
containing IgG antibody (MacLennan,
1972). Although IgG aggregation during
storage or during the assay procedure
FIG. 2.-Comparison of pre- and post-operat-
ive breast cancer sera for inhibition of K
cell lysis of antibody-coated Chang cells.
Each point represents serum from a differ-
ent patient.
might be expected to be related to the
serum concentration of IgG, there was no
direct correlation between IgG concentra-
tion and the K cell inhibitory activity of
breast cancer sera (correlation coefficient
-0.46).
Gel-filtration using Ultrogel AcA34
was used for the partial characterization
of the inhibitory factor. The IgG-rich
fraction of all sera tested (either " in-
hibitory " or " non-inhibitory ") became
inhibitory after gel-filtration, presumably
because ofpartial denaturation during the
separation procedure. However, 3 of 4
" inhibitory " sera had additional activity
in fractions of higher molecular weight
than IgG, although no IgG could be
detected in these fractions by radial
immunodiffusion.
Inhibition of C' fixation
As immune complexes can have anti-
complementary activity, it was of interest
to compare normal and breast cancer sera
for inhibition of C' fixation (Table II).
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TABLE II.-Anticomplemnentary Activity
of Control and Breast Cancer Sera
Proportion of anti-
Group complementary sera*
Control 1/24 (4. 2°,)
Breast Cancer
Pooled 7/78 (9O0e)
Stage 1 1/20 (5- 0o)
Stage 2 0/16 (0%)
Stage 3 2/23 (8- 7%)
Stage 4 4/19 (21.1%)
* All anticomplementary sera had in-
hibition titres of > 1'128.
Only Stage 4 sera showed increased anti-
complementary activity compared to
normal sera (P 0.02). There was no
correlation between the anti-complemen-
tary activity of individual sera and their
capacity to inhibit K cell cytotoxicity.
DISCUSSION
Approximately 3900 of breast cancer
sera, but less than 80% of normal sera,
inhibited K cell cytotoxicity by more
than 3000. The effect was present at all
stages ofthe disease, in both pre-operative
and post-operative patients, and was age-
independent. Inhibition was not due to
rheumatoid factor and apparently not to
anti-HLA antibodies and did not correlate
with serum IgG levels or anti-comple-
mentary activity.
Characterization of the K cell in-
hibitory factor by gel-filtration on an
Ultrogel column revealed that the IgG
fraction of both " inhibitory " and " non-
inhibitory" sera acquired inhibitory
activity. A similar effect has been noted
using ion-exchange chromatography
(MacLennan and Howard, 1972). Despite
this, additional inhibitory activity was
found in fractions of higher molecular
weight than monomeric IgG. As these
fractions contained no IgG detectable by
radial immunodiffusion, we cannot at
this stage conclude that the inhibitory
factor is an IgG-containing immune com-
plex.
Anti-complementary activity of breast
cancer sera had a much lower incidence
than K cell inhibition, and the 2 effects
did notcorrelate. Asanti-complementary
activity is usually mediated by large
immune complexes (Weigle, 1961), it is
unlikely that this type of complex is
responsible for K cell inhibition by breast
cancer sera.
There have been previous reports of
serum inhibition of K cell killing. Jewell
and MacLennan (1973) found inhibitory
immune complexes in the sera of patients
with inflammatory bowel disease, while
Matthews et al. (1976) reported that sera
from rats bearing a squamous cell carci-
noma inhibited K cell activity. In this
latter report, the effect was also in-
dependent of the stage of tumour growth.
As inhibition was noted with control
sera, albeit to a lesser extent, the in-
hibitory factor may be a normal com-
ponent of serum which is elevated in
some breast cancer sera. Proof of this
requires further characterization of the
Kcell inhibitoryfactor,andthisiscurrently
being attempted. Whatever the nature
of the factor it may well contribute to the
immunosuppression in a proportion of
breast cancer patients.
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